RT Journal Article SR Electronic T1 Beneficial effect of azithromycin in children with diffuse parenchymal lung disease JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P3495 VO 44 IS Suppl 58 A1 Caroline Perisson A1 Ralph Epaud A1 Michael Fayon A1 Nadia Nathan A1 Guillaume Thouvenin A1 Harriet Corvol A1 Annick Clement A1 RespiRare Group YR 2014 UL http://erj.ersjournals.com/content/44/Suppl_58/P3495.abstract AB Introduction : Diffuse Parenchymal Lung Disease (DPLD) in children is a heterogeneous group of disorders characterized by inflammation and/or remodeling of the lung parenchyma. The aim of this study was to evaluate the benefic effect of azithomycin (AZM) in children with DPLD.Methods : The study included 8 children with DPLD. Four had a diagnosis of surfactant disorder. The median age at diagnostic was 8 months (1;24). AZM was introduced at a median age of 51.6 months (15;109), at a dose of 20 mg/kg 3 days a week. The median duration of the follow up was 4.5 years (1,5;6,5).Results : After 1 year of AZM, all the patients had an improvement in their quality of life, a weight gain of 18% (10;34), allowing to stop enteral nutrition in 2 patients. A significant decrease in breath per min (BPM) was documented (34.3 BPM vs 51.7). This was associated with an increase in Pa02 (63,5 mmHg vs 72,6).Conclusion : AZM had a benefic effect on general condition and respiratory parameters in children with DPLD, after only one year of treatment. Further studies are necessary to confirm these results; early introduction of AZM can be a corticosteroid saver.